SOBIN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
SOBIN FAQ
What was Swedish Orphan Biovitrum Ab’s price range in the past 12 months?
Currently, no data Available
What is Swedish Orphan Biovitrum Ab’s market cap?
Swedish Orphan Biovitrum Ab’s market cap is $286.96B.
When is Swedish Orphan Biovitrum Ab’s upcoming earnings report date?
Swedish Orphan Biovitrum Ab’s upcoming earnings report date is Oct 27, 2026 which is in 94 days.
How were Swedish Orphan Biovitrum Ab’s earnings last quarter?
Swedish Orphan Biovitrum Ab released its earnings results on Jul 16, 2026. The company reported $5.641 earnings per share for the quarter, missing the consensus estimate of $6.101 by -$0.46.
Is Swedish Orphan Biovitrum Ab overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum Ab’s price is currently Undervalued.
Does Swedish Orphan Biovitrum Ab pay dividends?
Swedish Orphan Biovitrum Ab does not currently pay dividends.
What is Swedish Orphan Biovitrum Ab’s EPS estimate?
Swedish Orphan Biovitrum Ab’s EPS estimate is 11.24.
How many shares outstanding does Swedish Orphan Biovitrum Ab have?
Swedish Orphan Biovitrum Ab has 357,412,840 shares outstanding.
What happened to Swedish Orphan Biovitrum Ab’s price movement after its last earnings report?
Swedish Orphan Biovitrum Ab reported an EPS of $5.641 in its last earnings report, missing expectations of $6.101. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum Ab?
Currently, no hedge funds are holding shares in MX:SOBIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Swedish Orphan Biovitrum Ab
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
SOBIN Stock 12 Month Forecast
Average Price Target
$914.36